ADC Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ADC Therapeutics's estimated annual revenue is currently $16.9M per year.
- ADC Therapeutics's estimated revenue per employee is $53,009
- ADC Therapeutics's total funding is $691.6M.
- ADC Therapeutics's current valuation is $1.3B. (January 2022)
Employee Data
- ADC Therapeutics has 319 Employees.
- ADC Therapeutics grew their employee count by 1% last year.
ADC Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Global Medical Affairs | Reveal Email/Phone |
2 | Head Quality Control | Reveal Email/Phone |
3 | Head Process Quality and CMC Analytical | Reveal Email/Phone |
4 | Head Manufacturing Technical Operations | Reveal Email/Phone |
5 | Head Quality | Reveal Email/Phone |
6 | VP, Global Early Stage Clinical Development - Oncology | Reveal Email/Phone |
7 | Controller | Reveal Email/Phone |
8 | Head, Chemical Development & Manufacturing | Reveal Email/Phone |
9 | Head Global Pharmagovigilance | Reveal Email/Phone |
10 | VP Deputy General Counsel and Assistant Secretary | Reveal Email/Phone |
ADC Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is ADC Therapeutics?
ADC Therapeutics is a Biotechnology company located in Lausanne, Vaud, Switzerland.
keywords:N/A
$691.6M
Total Funding
319
Number of Employees
$16.9M
Revenue (est)
1%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
ADC Therapeutics News
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of Buy from Analysts. Posted by admin on Apr 16th, 2022.
HC Wainwright dropped their price objective on shares of ADC Therapeutics from $55.00 to $54.00 and set a buy rating on the stock in a research...
InvestorsObserver is giving ADC Therapeutics SA (ADCT) an Analyst Rating Rank of 69, meaning ADCT is ranked higher by analysts than 69% of...
ADC Therapeutics SA headquarted at Biopôle in Epalinges close to Lausanne is a late clinical-stage oncology-focused biotechnology company developing antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. The company announced today the pricing of the in ...
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors.The company has filed a regis ...
Other Companies in Lausanne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $97.1M | 370 | -2% | N/A |
#2 | $3.5M | 376 | -2% | N/A |
#3 | $113.1M | 431 | 3% | N/A |
#4 | $199.1M | 590 | 5% | N/A |
#5 | $98.8M | 608 | 5% | N/A |